viewCollagen Solutions PLC

Collagen Sol PLC - Trading Update

RNS Number : 5060V
Collagen Solutions PLC
09 April 2019


9 April 2019


Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")


Trading Update

Delivering on our growth strategy


Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces a trading update for the year ended 31 March 2019.


Continuing the growth seen in the first half of the year, revenue for the full year is expected to be ahead of market expectations at £4.15m (2018: £3.50m), reflecting growth for the full year of 18%. Revenue from agreements to develop collagen products on behalf of third parties continued to contribute significantly to the business in the second half and will make up approximately 33% of our revenue for the year.


The Company is anticipated to show a lower than expected loss before tax for the year due to the improved top line as well as the sale of the Company's holding in Jellagen Limited.


The Company continues to await feedback from its Notified Body regarding the status of the CE mark for ChondroMimetic. In preparation for the approval, and as previously announced, the Company has established several distribution partners in select countries in Europe and Asia in anticipation of this.


Group cash balances at the year-end were also better than expected at approximately £1.7m (2018: £5.0m). Since the year-end, the Company has been trading in line with managements' expectations and continues to build on the progress made in FY 2019, supported by the new business gained in the second half of the last financial year and current pipeline of new deals in process.


Jamal Rushdy, CEO of Collagen Solutions, commented: "We are pleased with our delivery of high double-digit growth within our core business representing a substantial turn-around of performance from our prior financial year. In addition, our increased mix of development services is a positive leading indicator of success in our strategy to move up the value chain. We look forward to providing a further update when we announce our preliminary results in July."


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.




Collagen Solutions Plc


Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO




Cenkos Securities Plc (Nominated Adviser and Broker)

Tel: 0207 397 8900

Giles Balleny / Stephen Keys




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected] 

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Collagen Solutions PLC

Price: 3.2099

Market: LSE
Market Cap: £14.24 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Collagen Solutions reports strong growth in its tissue business in first half

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence update Proactive London's Andrew Scott on first half performance - their third consecutive six-month period of double-digit sales growth. Revenues increased by 14% to £2.23mln in the period ended September 30. Tissue sales more...

on 3/12/19